Bridging the Inter-Domain Gap through Low-Level Features for Cross-Modal Medical Image Segmentation

This paper addresses the task of cross-modal medical image segmentation by exploring unsupervised domain adaptation (UDA) approaches. We propose a model-agnostic UDA framework, LowBridge, which builds on a simple observation that cross-modal images share some similar low-level features (e.g., edges) as they are depicting the same structures. Specifically, we first train a generative model to recover the source images from their edge features, followed by training a segmentation model on the generated source images, separately. At test time, edge features from the target images are input to the pretrained generative model to generate source-style target domain images, which are then segmented using the pretrained segmentation network. Despite its simplicity, extensive experiments on various publicly available datasets demonstrate that \proposed achieves state-of-the-art performance, outperforming eleven existing UDA approaches under different settings. Notably, further ablation studies show that \proposed is agnostic to different types of generative and segmentation models, suggesting its potential to be seamlessly plugged with the most advanced models to achieve even more outstanding results in the future. The code is available at https://github.com/JoshuaLPF/LowBridge.

Discovering robust biomarkers of neurological disorders from functional MRI using graph neural networks: A Review

Graph neural networks (GNN) have emerged as a popular tool for modelling functional magnetic resonance imaging (fMRI) datasets. Many recent studies have reported significant improvements in disorder classification performance via more sophisticated GNN designs and highlighted salient features that could be potential biomarkers of the disorder. In this review, we provide an overview of how GNN and model explainability techniques have been applied on fMRI datasets for disorder prediction tasks, with a particular emphasis on the robustness of biomarkers produced for neurodegenerative diseases and neuropsychiatric disorders. We found that while most studies have performant models, salient features highlighted in these studies vary greatly across studies on the same disorder and little has been done to evaluate their robustness. To address these issues, we suggest establishing new standards that are based on objective evaluation metrics to determine the robustness of these potential biomarkers. We further highlight gaps in the existing literature and put together a prediction-attribution-evaluation framework that could set the foundations for future research on improving the robustness of potential biomarkers discovered via GNNs.